Imaging and medical and surgical robotics

Within five months, therapeutic Innovations formalized six projects, four within the first axis (gene and chemistry to the drug) and two of the second (Imaging and medical and surgical robotics). All these records contain an amount of 17 million euros of public and private competition. This adds the implementation to Strasbourg of a cyclotron for production in two years of radioactive isotopes consumed in diagnostic medical imaging. The decision by the Scarlets company Cyclopharma to invest EUR 6 million was supported by the labelling of the Alsatian pole.

Gene and chemistry to the drug.

Novalix is aimed at the development and marketing of an integrated tool for the design and development of small molecules for cancer-fighting applications. The goal is to develop a platform for screening to select small molecules to inhibit the association between the receiver and the Beta-catenin. Project duration: two years. (Partners: Novalyst Discovery, Alix Pharmaceuticals, Institute of genetics and molecular biology and cell-IGBMC, Inserm, CNRS, université Louis-Pasteur.)

Aramis has the ambition to identify new candidates drugs for the treatment of Parkinson's disease. The project aims to discover and optimize of new protein G (GPCRS)-coupled receptor ligands. The final objective is the characterization of new clinical candidates. Duration: three years. (Partners: Faust Pharmaceuticals, Prestwick Chemicals, laboratory of interactions pharmacochimie cellular CNRS and Faculty of pharmacy, IFR 85 of the université Louis-Pasteur.)

Oligoplus wants to develop new tools for the diagnosis and analysis, based on the rapid detection of genes. The project relies on the development of new molecular tools with superior properties to those of conventional oligonucleotide, which makes it potentially the most powerful tools for molecular hybridization. Duration: two years. (Partners: Polyplus Transfection, Chemtox, genetic Chemistry Laboratory, CNRS-université Louis-Pasteur.)

Excilot proposes the development of new formulations to enhance the pharmacological potential of drugs. This project aims to optimize the use of lipid, surfactant type functional excipients and cosolvent to make oral new molecular entities and improve their pharmacological potential. Duration: three years. (Partners: Capsugel, carrier of the project, Gattefosse, biorganique Chemistry Laboratory, CNRS-université Louis-Pasteur.)

Imaging and medical and surgical robotics.

Anubis: it is a development of transgastrique surgery by dedicated surgical tools and ad hoc formations. The introduction of perspective in the abdomen of the patient, to the realization of the operative gesture through a miniature camera, was the largest transfer surgery world has known in the 20th century: the era of "minimally invasive" surgery This revolution by French surgeons, has enabled the development of a substantial market controlled by us, Japanese and German companies. This market is poised for a new swing, linked to the emergence of a new surgical technique original, transgastrique surgery, which will replace term traditional laparoscopic surgery. The Anubis project has the ambition to position itself as a world leader of this new technique. Duration: three years. (Partners: Ircad, Lsiit, université Louis-Pasteur-CNRS, Karl Storz, Germany.)

Stetau: project for development of an electronic stethoscope communicating on PC or PDA to the registration, processing and exploitation of auscultation sounds pulmonary and cardiac. The record also includes the development of tools for analysis of the signal to its Visual and acoustic restitution, the search for markers of specific pathologies, the definition of a standardized format for archiving, analysis and transmission of the auscultatory sounds. Duration: 18 months. (Partners: Alcatel to Illkirch, Laennext Strasbourg, Strasbourg hospitals.)